Search





Search





Markets
/
Stocks
/
nasdaq-onco
/

Onconetix Inc

ONCO

Add to Watchlist

0.374USD

-0.016-4.10%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

4.29MMarket Cap

LossP/E TTM



Onconetix Inc

0.374

-0.016-4.10%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Onconetix Inc

Currency: USD Updated: 2026-05-15

Key Insights

Onconetix Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Onconetix Inc's Score

Industry at a Glance

Industry Ranking

120 / 155

Overall Ranking

475 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Onconetix Inc Highlights

StrengthsRisks

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1294.63% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 815.37K.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 26.70K shares, increasing 7.56% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.54.

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Onconetix Inc is 6.57, ranking 136 out of 155 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 303.60K, representing a year-over-year decrease of 57.36%, while its net profit experienced a year-over-year decrease of 119.13%.

Score

Industry at a Glance

Previous score

6.57

Change



Financials

4.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.14

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Onconetix Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Onconetix Inc is 7.52, ranking 64 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -153.33% below the recent high of 0.00 and -1258868.89% above the recent low of -56.65.

Score

Industry at a Glance

Previous score

7.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/155

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

No earnings forecast score is currently available for Onconetix Inc. The Pharmaceuticals industry's average is 7.89.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Onconetix Inc is 3.02, ranking 151 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.69 and the support level at 0.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.04

Change

-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.119

Neutral

RSI(14)

28.271

Sell

STOCH(KDJ)(9,3,3)

8.317

Oversold

ATR(14)

0.069

Low Volatility

CCI(14)

-70.835

Neutral

Williams %R

97.021

Oversold

TRIX(12,20)

-4.551

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.392

Sell

MA10

0.436

Sell

MA20

0.566

Sell

MA50

1.441

Sell

MA100

3.955

Sell

MA200

9.349

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Onconetix Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 3.85%, representing a quarter-over-quarter decrease of 34.62%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Altos Venture AG

54.65K

+761.52%

Geode Capital Management, L.L.C.

661.00

DRW Securities, LLC

7.81K

-36.81%

HRT Financial LP

-100.00%

Abante Asesores Gestión, S.G.I.I.C., S.A.

2.94K

XTX Markets LLC

2.17K

UBS Financial Services, Inc.

1.84K

+67.21%

Bruhlmann (Christian)

1.44K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Onconetix Inc is 1.79, ranking 141 out of 155 in the Pharmaceuticals industry. The company's beta value is 2.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.